ArticleCell reports. Medicine2023

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.

Eric M Desjardins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.